Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Stefanie Johns to the Company's Scientific Advisory Board. The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform and other therapeutics. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.
Dr. Stefanie Johns, Ph.D. is the Associate Director, Regulatory Affairs at Enable Injections, LLC, a company specializing in the development and manufacture of advanced wearable infusion devices for use in combination products. Dr. Johns completed her graduate work in protein biochemistry at the University of Cincinnati College of Medicine under the direction of Dr. Andrew Herr, Ph.D., whom also contributed to the development of the BioLexa Platform technology. After graduate school, Dr. Johns joined Xavier Health Initiatives as the Program Manager where she assisted with collaborative initiatives with both pharmaceutical and medical device industry leaders, division leaders from the United States Food and Drug Administration, and members of the Senate Health, Education Labor & Pensions committee. She continued her career in regulatory affairs providing strategic regulatory guidance for medical device, drug, and drug-device combination product development programs at Meridian Bioscience and Camargo Pharmaceutical Services. While at Camargo, Dr. Johns led the planning and implementation of the early regulatory strategy for the BioLexa program.
Dr. Johns commented, "I am excited to continue working with Hoth Therapeutics on the development of the BioLexa Platform as a novel therapeutic for treatment of dermatological and chronic wound disorders. Chronic dermatological diseases, including atopic dermatitis, cause significant burden on patients and their families and it is important to have novel treatment options available, particularly for patients whose disease is not currently controlled by existing therapies."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.
